Immunovant's stock was trading at $14.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IMVT stock has decreased by 69.8% and is now trading at $4.27. View which stocks have been most impacted by COVID-19.
Who bought IMVT stock in the last quarter?
Apr 13, 2022 · Immunovant's stock was trading at $14.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IMVT stock has decreased by 69.8% and is now trading at $4.27. View which stocks have been most impacted by COVID-19.
Why did immunovant's stock fall today?
Find the latest Immunovant, Inc. (IMVT) stock quote, history, news and other vital information to help you with your stock trading and investing.
Why is Novartis’ imvt-1401 trial halted?
Feb 02, 2021 · A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Immunovant Inc (Symbol: IMVT) entered into oversold territory, hitting an …
Does imvt-1401 cause high cholesterol?
Feb 17, 2021 · Shares of clinical-stage biopharmaceutical company Immunovant (NASDAQ: IMVT) are rising sharply on Wednesday morning and are up by 13.5% as of 11:55 a.m. EST, after jumping by as much as 15.4% ...
Why did IMVT go down?
Is IMVT stock a good buy?
Why is Immunovant stock down?
Immunovant (NASDAQ: IMVT), a company developing a monoclonal antibody for the treatment of autoimmune diseases, is down almost 25% after receiving a cash injection of $200 million from Roivant Sciences.
Should I sell Immunovant?
Is Immunovant a buy right now?
10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last year. There are currently 1 sell...
How has Immunovant's stock been impacted by Coronavirus (COVID-19)?
Immunovant's stock was trading at $14.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Orga...
When is Immunovant's next earnings date?
Immunovant is scheduled to release its next quarterly earnings announcement on Tuesday, June 7th 2022. View our earnings forecast for Immunovant .
How were Immunovant's earnings last quarter?
Immunovant, Inc. (NASDAQ:IMVT) issued its earnings results on Friday, February, 4th. The company reported ($0.36) earnings per share (EPS) for the...
What price target have analysts set for IMVT?
10 brokerages have issued 1-year price targets for Immunovant's shares. Their forecasts range from $7.00 to $20.00. On average, they anticipate Imm...
Who are Immunovant's key executives?
Immunovant's management team includes the following people: Dr. Peter Salzmann M.B.A. , M.D., CEO & Director (Age 53, Pay $1.02M) Ms. Pamela Yan...
Who are some of Immunovant's key competitors?
Some companies that are related to Immunovant include Twist Bioscience (TWST) , Iovance Biotherapeutics (IOVA) , ImmunityBio (IBRX) , Valneva (...
What other stocks do shareholders of Immunovant own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include salesforce.com (CRM) , N...
What is Immunovant's stock symbol?
Immunovant trades on the NASDAQ under the ticker symbol "IMVT."
The company is pausing one of its clinical studies
A Fool since 2019, Prosper's writing focuses primarily on the healthcare sector. Passionate about teaching and learning, he enjoys helping others make better decisions about their finances -- and enjoys it just as much when they return the favor. In his free time, you'll find him curling up with a good book or doing math.
What happened?
Shares of Immunovant ( NASDAQ:IMVT), a clinical-stage biopharmaceutical company, were down by 43.2% as of 2:57 p.m. EST on Tuesday, after plunging by as much as 48% earlier in the day. The losses came after Immunovant announced an update regarding one of its ongoing clinical trials.
So what
Immunovant is developing IMVT-1401 for the treatment of several conditions, including thyroid eye disease (TED). During a phase 2b clinical trial, Immunovant recorded cases of elevated total cholesterol and LDL levels in patients treated with IMVT-1401. LDL stands for low-density lipoprotein, and it is a form of cholesterol.
Now what
The market doesn't like uncertainty, and while we don't know for sure whether the higher LDL observed in patients taking IMVT-1401 after 12 weeks was due to the experimental medicine, today's news was enough to scare off investors.
How much of Immunovant stock is held by insiders?
Only 1.90% of the stock of Immunovant is held by insiders.
What is the ticker symbol for Immunovant?
Immunovant trades on the NASDAQ under the ticker symbol "IMVT."
What is immunovant in clinical trials?
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
What is the P/E ratio of Immunovant?
The P/E ratio of Immunovant is -6.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Where is Immunovant located?
Immunovant's mailing address is 320 WEST 37TH STREET, NEW YORK NY, 10018. The company can be reached via phone at 917-580-3099 or via email at [email protected].
Does Immunovant pay dividends?
Immunovant does not currently pay a dividend.
Who is investigating Immunovant?
SAN DIEGO, CA and NEW YORK, NY / ACCESSWIRE / October 11, 2021 / Shareholder rights law firm Robbins LLP announces that is investigating Immunovant, Inc. (NASDAQ:IMVT) to determine whether certain Immunovant officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company.
What is the net loss for the company in 2021?
Other increases include higher legal, professional, and other administrative costs to support our personnel growth and operations as a public company. Net Loss: Net loss was $28.2 million ($0.29 per common share) for the three months ended March 31, 2021, compared to $20.6 million ($0.38 per common share) for the three months ended March 31, 2020.
How to access Immunovant webcast?
To access the webcast, please visit Immunovant’s website at www.immunovant.com. Participants may also dial in using the numbers provided below: Toll Free: 1-877-407-9039Toll/International: 1-201-689-8470 An archived webcast recording will be available on the Immunovant’s website for a limited time.
What is the Vickers top buyer and seller report?
Daily – Vickers Top Buyers & Sellers for 08/31/2021 The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
How does MarketBeat calculate stock ratings?
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Does MarketBeat like Immunovant?
MarketBeat users like Immunovant stock more than the stock of other Medical companies. 83.75% of MarketBeat users gave Immunovant an outperform vote while medical companies recieve an average of 67.56% outperform votes by MarketBeat users.
